INmune Bio, Inc. (Nasdaq: INMB) is a clinical-stage immunology company that is exclusively focused on modulating components of the Innate Immune system to treat diseases. The company has 5 clinical programs in phase 1 or phase 2 in 2020 between two unique product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for cancer (INB03), Alzheimer’s (XPro1595), and NASH (LivNate). The Innate Immune Priming Platform includes INKmune aimed at priming the patient’s NK cells to eliminate the minimal residual disease in patients with cancer. To learn more, please visit www.inmunebio.com.
Back to All Events
Earlier Event: January 16
Neubase Therapeutics, Inc. (NASDAQ: NBSE) San Francisco Keynote Speaker Luncheon Event
Later Event: February 25
Hecla Mining Company (NYSE: HL) West Palm Beach Keynote Speaker Luncheon Event